Sirolimus plus fulvestrant for advanced hormone-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination treatment (sirolimus and fulvestrant) for people with advanced breast cancer that is HR+ and HER2-. It may help if your previous hormonal therapy plus a CDK4/6 inhibitor is no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced or metastatic breast cancer that is hormone receptor positive (HR+) and HER2 negative.
- You must have already received at least one prior hormonal therapy combined with a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib).
- You should have at least one tumor that can be measured on scans (like a CT or MRI).
- You should be able to perform daily activities with minimal help (ECOG score of 0 or 1).
- You must not have been previously treated with fulvestrant or other similar targeted therapies.
- You must agree to provide blood or tumor samples for biomarker testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of the drug sirolimus (bound to albumin) combined with two other drugs (palbociclib and fulvestrant) for advanced breast cancer. It aims to see if this combination is safe and effective for people with the HR-positive, HER2-negative subtype.
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
Hear when a new HR+/HER2- Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.